These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14567545)

  • 41. Synthesis and evaluation of 4,5-dihydro-5-methylisoxazolin-5-carboxamide derivatives as VLA-4 antagonists.
    Soni A; Rehman A; Naik K; Dastidar S; Alam MS; Ray A; Chaira T; Shah V; Palle VP; Cliffe IA; Sattigeri VJ
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1482-5. PubMed ID: 23312947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.
    Yang GX; Chang LL; Truong Q; Doherty GA; Magriotis PA; de Laszlo SE; Li B; MacCoss M; Kidambi U; Egger LA; McCauley E; Van Riper G; Mumford RA; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1497-500. PubMed ID: 12031328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The interaction affinity between vascular cell adhesion molecule-1 (VCAM-1) and very late antigen-4 (VLA-4) analyzed by quantitative FRET.
    Chakraborty S; Hu SY; Wu SH; Karmenyan A; Chiou A
    PLoS One; 2015; 10(3):e0121399. PubMed ID: 25793408
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.
    Kopka IE; Young DN; Lin LS; Mumford RA; Magriotis PA; MacCoss M; Mills SG; Van Riper G; McCauley E; Egger LE; Kidambi U; Schmidt JA; Lyons K; Stearns R; Vincent S; Colletti A; Wang Z; Tong S; Wang J; Zheng S; Owens K; Levorse D; Hagmann WK
    Bioorg Med Chem Lett; 2002 Feb; 12(4):637-40. PubMed ID: 11844689
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.
    Rice GP; Hartung HP; Calabresi PA
    Neurology; 2005 Apr; 64(8):1336-42. PubMed ID: 15851719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship between molecular and cellular dissociation rates for VLA-4/VCAM-1 interaction in the absence of shear stress.
    Zwartz G; Chigaev A; Foutz T; Larson RS; Posner R; Sklar LA
    Biophys J; 2004 Feb; 86(2):1243-52. PubMed ID: 14747358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 2,6-Quinolinyl derivatives as potent VLA-4 antagonists.
    Lassoie MA; Broeders F; Collart P; Defrère L; de Laveleye-Defais F; Demaude T; Gassama A; Guillaumet G; Hayez JC; Kiss L; Knerr L; Nicolas JM; Norsikian S; Quéré L; Routier S; Verbois V; Provins L
    Bioorg Med Chem Lett; 2007 Jan; 17(1):142-6. PubMed ID: 17035017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells.
    Wang MW; Consoli U; Lane CM; Durett A; Lauppe MJ; Champlin R; Andreeff M; Deisseroth AB
    Cell Growth Differ; 1998 Feb; 9(2):105-12. PubMed ID: 9486846
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin α4β1.
    Vanderslice P; Woodside DG; Caivano AR; Decker ER; Munsch CL; Sherwood SJ; Lejeune WS; Miyamoto YJ; McIntyre BW; Tilton RG; Dixon RA
    Biochem Biophys Res Commun; 2010 Oct; 400(4):619-24. PubMed ID: 20807504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immobilized stromal cell-derived factor-1alpha triggers rapid VLA-4 affinity increases to stabilize lymphocyte tethers on VCAM-1 and subsequently initiate firm adhesion.
    DiVietro JA; Brown DC; Sklar LA; Larson RS; Lawrence MB
    J Immunol; 2007 Mar; 178(6):3903-11. PubMed ID: 17339490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.
    Gong Y; Barbay JK; Dyatkin AB; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Ballentine SA; Hageman WE; Masucci JA; Maryanoff BE; Damiano BP; Andrade-Gordon P; Hlasta DJ; Hornby PJ; He W
    J Med Chem; 2006 Jun; 49(11):3402-11. PubMed ID: 16722660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cross talk between alpha(v)beta3 and alpha4beta1 integrins regulates lymphocyte migration on vascular cell adhesion molecule 1.
    Imhof BA; Weerasinghe D; Brown EJ; Lindberg FP; Hammel P; Piali L; Dessing M; Gisler R
    Eur J Immunol; 1997 Dec; 27(12):3242-52. PubMed ID: 9464812
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adhesion molecule mechanisms mediating monocyte migration through synovial fibroblast and endothelium barriers: role for CD11/CD18, very late antigen-4 (CD49d/CD29), very late antigen-5 (CD49e/CD29), and vascular cell adhesion molecule-1 (CD106).
    Shang XZ; Lang BJ; Issekutz AC
    J Immunol; 1998 Jan; 160(1):467-74. PubMed ID: 9552005
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Subsecond induction of alpha4 integrin clustering by immobilized chemokines stimulates leukocyte tethering and rolling on endothelial vascular cell adhesion molecule 1 under flow conditions.
    Grabovsky V; Feigelson S; Chen C; Bleijs DA; Peled A; Cinamon G; Baleux F; Arenzana-Seisdedos F; Lapidot T; van Kooyk Y ; Lobb RR; Alon R
    J Exp Med; 2000 Aug; 192(4):495-506. PubMed ID: 10952719
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Superoxide activates very late antigen-4 on an eosinophil cell line and increases cellular binding to vascular cell adhesion molecule-1.
    Chuang KP; Tsai WS; Wang YJ; Shieh CC
    Eur J Immunol; 2003 Mar; 33(3):645-55. PubMed ID: 12616485
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alpha4beta1 integrin (VLA-4) blockade attenuates both early and late leukocyte recruitment and neointimal growth following carotid injury in apolipoprotein E (-/-) mice.
    Barringhaus KG; Phillips JW; Thatte JS; Sanders JM; Czarnik AC; Bennett DK; Ley KF; Sarembock IJ
    J Vasc Res; 2004; 41(3):252-60. PubMed ID: 15153775
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthetic study of VLA-4/VCAM-1 inhibitors: synthesis and structure-activity relationship of piperazinylphenylalanine derivatives.
    Saku O; Ohta K; Arai E; Nomoto Y; Miura H; Nakamura H; Fuse E; Nakasato Y
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1053-7. PubMed ID: 18160288
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Imide and lactam derivatives of N-benzylpyroglutamyl-L-phenylalanine as VCAM/VLA-4 antagonists.
    Tilley JW; Kaplan G; Rowan K; Schwinge V; Wolitzky B
    Bioorg Med Chem Lett; 2001 Jan; 11(1):1-4. PubMed ID: 11140722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A small molecule alpha4beta1/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependence.
    Egger LA; Cao J; McCallum C; Kidambi U; Van Riper G; McCauley E; Mumford RA; Lanza TJ; Lin LS; de Laszlo SE; Young DN; Yang G; Dean DC; Raab CE; Wallace MA; Jones AN; Hagmann WK; Schmidt JA; Pepinsky RB; Scott DM; Lee WC; Cornebise MA; Detmers PA
    J Pharmacol Exp Ther; 2003 Sep; 306(3):903-13. PubMed ID: 12766251
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vascular cell adhesion molecule 1 (CD106) on primary human articular chondrocytes: functional regulation of expression by cytokines and comparison with intercellular adhesion molecule 1 (CD54) and very late activation antigen 2.
    Kienzle G; von Kempis J
    Arthritis Rheum; 1998 Jul; 41(7):1296-305. PubMed ID: 9663488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.